A US clinical study involving Irving Weissman of Ben Gurion University is using the antibody Magrolimab to enhance “scavenger macrophages” – cancer cell-eating white blood cells. Magrolimab blocks the CD47 molecule that cancer cells produce to signal “don’t eat me” to the macrophages.

https://in.bgu.ac.il/en/pages/news/bgu_stanford.aspx